Oculis (OCS) Competitors

Akero Therapeutics (NASDAQ:AKRO) and Oculis (NASDAQ:OCS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, community ranking, valuation and profitability.

Does the MarketBeat Community believe in AKRO or OCS?

Akero Therapeutics received 84 more outperform votes than Oculis when rated by MarketBeat users. However, 91.67% of users gave Oculis an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote.

Company	Underperform	Outperform
Akero Therapeutics	Outperform Votes 117 65.36%	Underperform Votes 62 34.64%
Oculis	Outperform Votes 33 91.67%	Underperform Votes 3 8.33%

Do analysts rate AKRO or OCS?

Akero Therapeutics currently has a consensus price target of $76.29, suggesting a potential upside of 86.11%. Oculis has a consensus price target of $30.25, suggesting a potential upside of 67.59%. Given Akero Therapeutics' higher probable upside, research analysts clearly believe Akero Therapeutics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oculis	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is AKRO or OCS more profitable?

Akero Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,043.28%. Akero Therapeutics' return on equity of -32.46% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akero Therapeutics	N/A	-32.46%	-29.83%
Oculis	-8,043.28%	-71.31%	-56.85%

Do institutionals and insiders hold more shares of AKRO or OCS?

22.3% of Oculis shares are owned by institutional investors. 7.9% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has better valuation & earnings, AKRO or OCS?

Oculis has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akero Therapeutics	N/A	N/A	-$151.76M	-$3.75	-10.93
Oculis	$980K	804.18	-$98.92M	-$2.31	-7.81

Which has more volatility and risk, AKRO or OCS?

Akero Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.

Does the media favor AKRO or OCS?

In the previous week, Oculis had 1 more articles in the media than Akero Therapeutics. MarketBeat recorded 7 mentions for Oculis and 6 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 0.96 beat Oculis' score of 0.65 indicating that Akero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akero Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Akero Therapeutics and Oculis tied by winning 8 of the 16 factors compared between the two stocks.